导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.74% | 3947/4773 |
| 近一周 | -3.18% | 3832/5462 |
| 近一月 | -3.20% | 1606/5421 |
| 近一季 | -1.85% | 1086/5209 |
| 近半年 | -5.23% | 2791/4920 |
| 近一年 | -15.98% | 3744/4366 |
| 近两年 | 31.52% | 2217/2954 |
| 近三年 | 11.98% | 1699/2253 |
| 成立以来 | 19.71% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.54% 4667/4961 |
8.81% 2538/5312 |
- - |
- - |
| 2025 | 3.83% 3090/4813 |
-6.69% 3387/3635 |
4.31% 799/4076 |
11.00% 3216/4524 |
-3.88% 3354/4813 |
| 2024 | 30.34% 111/3463 |
-4.67% 1737/2808 |
-8.19% 2182/3014 |
43.85% 6/3129 |
3.53% 806/3463 |
| 2023 | 4.19% 239/2656 |
3.98% 1079/2280 |
-2.80% 671/2385 |
7.66% 30/2515 |
-4.26% 936/2655 |
| 2022 | -24.95% 1274/2207 |
-17.83% 1270/1919 |
1.85% 1413/2016 |
-15.39% 1282/2113 |
5.99% 401/2208 |
| 2021 | -3.20% 893/1822 |
-14.39% 1175/1255 |
6.74% 725/1330 |
4.32% 365/1466 |
1.55% 877/1822 |
| 2020 | 21.43% 690/1250 |
-9.53% 685/1028 |
9.38% 795/1067 |
20.91% 47/1164 |
1.49% 1026/1184 |
| 2019 | 45.43% 149/1092 |
46.33% 16/739 |
-6.28% 494/788 |
-3.93% 750/850 |
10.37% 143/918 |
| 2018 | -22.71% 257/834 |
- - |
-14.85% 499/631 |
-2.62% 293/660 |
-0.96% 6/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证全指证券公司ETF联接A VS. 长安沪深300非周期A(740101) |